Progetto OK 03-12-08
4-12-2008
17:26
Pagina 37
IPERTENSIONE E METABOLISMO - Considerazioni pratiche
Bibliografia 1. The World Health Report 1997: conquering, suffering, enriching humanity. World Health Organization, Geneva, 1997: p. 39. 2. Deedwania PC. Metabolic Sindrome and vascular disease - Is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004; 109: 2-4. 3. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752. 4. Alberti K and Zimmet P. Diagnosis and classification of diabetes mellitus and ist complications. Part 1: Diagnosis and classification of diabetes mellitus: Report on a WHO Consultation. Diabetic Med 1998; 15: 539-553. 5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. 6. International Diabetes Federation. The IDF Worldwide definition of the metabolic syndrome. Brussels IDF, 2005; Available at www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf> (accessed April 2006). 7. Zimmet P, Magliano D, Matsuzawa Y et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300. 8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome amonf US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. 9. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288; 2709-16. 10. Gu D, Reynolds Kristi, Wu X et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365: 1398-405. 11. Arcangeli A, Cosentino F, Cricelli C et al. Sindrome metabolica oggi: che cosa c'è da sapere, che cosa c'è da fare. Giornale Italiano di Medicina Interna 2006; 5, vol. 3 suppl. 3: 1-27. 12. Cicero AFG, Dormi A, Nascetti S et al. Relative role of major risk factors for type 2 Diabetes development in the historical cohort of the Brisighella Heart Study: an 8-years follow-up. Diabetes Med 2005; 22: 1263-6. 13. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581. 14. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005; 28: 2745-2749. 15. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study. Lancet 2004; 364: 937-52. 16. Hu G, Quiaio Q, Tumilehto J et al. DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076. 17. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States Adults. Circulation 2004; 110: 1245-1250. 18. Stern MP, Williams K, Hunt KJ. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 2005; 6: 3-6. 19. Hunt KJ, Resendez, Williams K et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all cause and cardiovascular mortality in San Antonio Hearth Study. Circulation 2004; 110: 1251-1257. 20. Kahn R, Buse J, Ferrannini E et al. The metabolic sindrome: time for a critical appraisal. Diabetes Care 2005; 28: 2289-2304. 21. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005; 28: 1769-177. 22. Mensah GA, Mokdad AH, Ford E, Narayan KM, Giles WH, Vinicor F et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004;22:485-504. 23. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115 Suppl 8A:24S-28S. 24. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokine in obesity-related diseases. Horm Res 2003;60(Suppl 3):56-9. 25. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506. 26. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1998;260:1917-21.
Vincenzo Immordino, Eugenio Roberto Cosentino, Alessia Fiorito
37